A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Doxorubicin HCl Liposomal (Doxil) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Trial Profile

A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Doxorubicin HCl Liposomal (Doxil) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Romidepsin (Primary) ; Doxorubicin liposomal
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Results (n=14) of the dose-escalation study of the combination of romidepsin and liposomal doxorubicin with preliminary data on the ORR, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2019.
    • 14 Nov 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top